Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. On that note, here are two growth stocks where the best is yet to come and one climbing an uphill battle.
One Growth Stock to Sell:
FOX (FOXA)
One-Year Revenue Growth: +15.7%
Founded in 1915, Fox (NASDAQ: FOXA) is a diversified media company, operating prominent cable news, television broadcasting, and digital media platforms.
Why Should You Dump FOXA?
- Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 3.9% over the last two years was below our standards for the consumer discretionary sector
- Forecasted revenue decline of 4.3% for the upcoming 12 months implies demand will fall off a cliff
FOX’s stock price of $53.50 implies a valuation ratio of 13.6x forward P/E. Read our free research report to see why you should think twice about including FOXA in your portfolio.
Two Growth Stocks to Watch:
Powell (POWL)
One-Year Revenue Growth: +27.4%
Originally a metal-working shop supporting local petrochemical facilities, Powell (NYSE: POWL) has grown from a small Houston manufacturer to a global provider of electrical systems.
Why Could POWL Be a Winner?
- Impressive 34.8% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Operating profits and efficiency rose over the last five years as it benefited from some fixed cost leverage
- Earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 209% annually
At $181 per share, Powell trades at 12.3x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.
Globus Medical (GMED)
One-Year Revenue Growth: +32.3%
With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE: GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures.
Why Do We Like GMED?
- Average constant currency growth of 61.4% over the past two years demonstrates its ability to grow internationally despite currency fluctuations
- Revenue outlook for the upcoming 12 months is outstanding and shows it’s on track to gain market share
- Earnings growth has trumped its peers over the last five years as its EPS has compounded at 13.8% annually
Globus Medical is trading at $59.20 per share, or 16.8x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
